AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ephrin type-A receptor 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P29317

UPID:

EPHA2_HUMAN

Alternative names:

Epithelial cell kinase; Tyrosine-protein kinase receptor ECK

Alternative UPACC:

P29317; B5A968; Q8N3Z2

Background:

Ephrin type-A receptor 2, also known as Epithelial cell kinase or Tyrosine-protein kinase receptor ECK, plays a pivotal role in various cellular processes. It binds ephrin-A family ligands, initiating bidirectional signaling that regulates cell migration, adhesion, proliferation, and differentiation. This receptor is crucial in development, angiogenesis, hindbrain development, and mammary gland development. It also influences lens transparency and bone remodeling.

Therapeutic significance:

The involvement of Ephrin type-A receptor 2 in Cataract 6, multiple types, underscores its therapeutic potential. Understanding its role could lead to innovative treatments for this and other diseases, including its function as a receptor for hepatitis C virus and human cytomegalovirus, suggesting avenues for antiviral strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.